References
- Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev 2021; 30: 200226. doi: 10.1183/16000617.0226-2020
- Mlika M, Lamzirbi O, Limam M, Mejri N, Ben Saad S, Chaouch N, et al. [Clinical and pathological profile of the pleural malignant mesothelioma: a retrospective study about 30 cases]. [French]. Rev Pneumol Clin 2018; 74: 427-35. doi: 10.1016/j.pneumo.2018.06.004
- Franko A; Kotnik N; Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478/raon-2018-0004
- Wen W, Xu D, Piao Y, Li X. Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis. Cancer Cell Int 2022 3; 22: 60. doi: 10.1186/s12935-022-02482-5
- Kovac V; Zwitter M; Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-144. doi: 10.2478/v10019-012-0032-0
- Royal College of Physicians (RCP). National Mesothelioma Audit Report 2020 (Audit Period 2016–18). [internet]. London, UK: RCP; 2020. [cited 2023 May]. Available at: www.rcplondon.ac.uk/projects/outputs/nationalmesothelioma-audit-report-2020-audit-period-2016-18
- Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo. org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2022; 33: 129-42. doi: 10.1016/j.annonc.2021.11.005
- Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, et al. FDA Approval Summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res 2022; 28: 446-51. doi: 10.1158/1078-0432.CCR-21-1466
- Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375-86. doi: 10.1016/S0140-6736(20)32714-8. Erratum in: Lancet 2021 20; 397: 670. doi: 10.1016/S0140-6736(21)00369-X
- Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018; 73(Suppl 1): i1-30. doi: 10.1136/thoraxjnl-2017-211321
- Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO Guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55: 1900953. doi: 10.1183/13993003.00953-2019
- Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014; 1844: 874-83. doi: 10.1016/j.bbapap.2013.12.007
- Kaya H, Demir M, Taylan M, Sezgi C, Tanrikulu AC, Yilmaz S, et al. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 2015; 16: 1403-7. doi: 10.7314/apjcp.2015.16.4.1403
- Livingstone I, Uversky VN, Furniss D, Wiberg A. The pathophysiological significance of fibulin-3. Biomolecules 2020; 10: 1294. doi: 10.3390/biom10091294
- Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27. doi: 10.1056/NEJMoa1115050. Erratum in: N Engl J Med 2012; 367: 1768. doi: 10.1056/NEJMc1213514
- Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, et al. Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. Anticancer Res 2017; 37: 1387-91. doi: 10.21873/anticanres.11460
- Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev 2021; 30: 210057. doi: 10.1183/16000617.00572021
- Ledda C, Senia P, Rapisarda V. Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on. Cancers 2018; 10: 203. doi: 10.3390/cancers10060203
- Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014; 69: 895-902. doi: 10.1136/thoraxjnl-2014-205205
- Sorino C, Mondoni M, Marchetti G, Agati S, Inchingolo R, Mei F, et al. Pleural mesothelioma: advances in blood and pleural biomarkers. J Clin Med 2023; 12: 7006. doi: 10.3390/jcm12227006
- Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 2015; 113: 963-9. doi: 10.1038/bjc.2015.286
- Tsim S, Alexander L, Kelly C, Shaw A, Hinsley S, Clark S, et al. Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. J Thorac Oncol 2021; 16: 1705-17. doi: 10.1016/j.jtho.2021.05.018
- Pei D, Li Y, Liu X, Yan S, Guo X, Xu X, et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis. Oncotarget 2017; 8: 13030-8. doi: 10.18632/on-cotarget.14712. Erratum in: Oncotarget 2018; 9: 21628. doi: 10.18632/oncotarget.25301
- Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 2016; 22: 3087-96. doi: 10.1158/1078-0432.CCR-15-1130
- Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 2017; 116: 731-41. doi: 10.1038/bjc.2017.22
- Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone CB 2nd, et al. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Lung Cancer 2021; 154: 5-12. doi: 10.1016/j.lungcan.2021.01.011
- Roshini A, Goparaju C, Kundu S, Nandhu MS, Longo SL, Longo JA, et al. The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling. Front Oncol 2022; 12: 1014749. doi: 10.3389/fonc.2022.1014749
- Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 2015; 49: 279-85. doi: 10.1515/raon-2015-0019
- Jiang Z, Ying S, Shen W, He X, Chen J, Xia H, et al. Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population. Dis Markers 2017; 2017: 1725354. doi: 10.1155/2017/1725354
- Rapisarda V, Caltabiano R, Musumeci G, Castrogiovanni P, Ferrante M, Ledda C, et al. Analysis of fibulin-3 after exposure to asbestos-like fibers. Environ Res 2017; 156: 381-7. doi: 10.1016/j.envres.2017.03.055
- Musk AW, de Klerk N, Reid A, Hui J, Franklin P, Brims F. Asbestos-related diseases. Int J Tuberc Lung Dis 2020; 24: 562-7. doi: 10.5588/ijtld.19.0645
- Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 1127-31. doi: 10.1038/sj.embor.7400033
- Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 1999; 18: 469-80. doi: 10.1016/s0945-053x(99)00038-4
- Tsuda T. Extracellular interactions between fibulins and transforming growth factor (TGF)-β in physiological and pathological conditions. Int J Mol Sci 2018; 19: 2787. doi: 10.3390/ijms19092787
- Odisio EG, Marom EM, Shroff GS, Wu CC, Benveniste APA, Truong MT, et al. Malignant pleural mesothelioma: diagnosis, staging, pitfalls and follow-up. Semin Ultrasound CT MR 2017; 38: 559-70. doi: 10.1053/j.sult.2017.07.006
- Lu Z, Zhang W, Huang K, Zhu M, Gu X, Wei D, et al. Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma. Diagnostics 2022; 2: 2210. doi: 10.3390/diagnostics12092210